These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

730 related items for PubMed ID: 11593409

  • 1. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
    Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q, Greene MI.
    Oncogene; 2001 Sep 20; 20(42):6018-25. PubMed ID: 11593409
    [Abstract] [Full Text] [Related]

  • 2. SHP-2 regulates the phosphatidylinositide 3'-kinase/Akt pathway and suppresses caspase 3-mediated apoptosis.
    Ivins Zito C, Kontaridis MI, Fornaro M, Feng GS, Bennett AM.
    J Cell Physiol; 2004 May 20; 199(2):227-36. PubMed ID: 15040005
    [Abstract] [Full Text] [Related]

  • 3. Formation of distinct signalling complexes involving phosphatidylinositol 3-kinase activity with stimulation of epidermal growth factor or insulin-like growth factor-I in human skin fibroblasts.
    Takahashi Y, Akanuma Y, Yazaki Y, Kadowaki T.
    J Cell Physiol; 1999 Jan 20; 178(1):69-75. PubMed ID: 9886492
    [Abstract] [Full Text] [Related]

  • 4. Multiple in vivo phosphorylated tyrosine phosphatase SHP-2 engages binding to Grb2 via tyrosine 584.
    Vogel W, Ullrich A.
    Cell Growth Differ; 1996 Dec 20; 7(12):1589-97. PubMed ID: 8959326
    [Abstract] [Full Text] [Related]

  • 5. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2.
    Saxton TM, Henkemeyer M, Gasca S, Shen R, Rossi DJ, Shalaby F, Feng GS, Pawson T.
    EMBO J; 1997 May 01; 16(9):2352-64. PubMed ID: 9171349
    [Abstract] [Full Text] [Related]

  • 6. ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.
    Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.
    Cancer Res; 2006 Aug 01; 66(15):7473-81. PubMed ID: 16885344
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
    Wu CJ, Chen Z, Ullrich A, Greene MI, O'Rourke DM.
    Oncogene; 2000 Aug 17; 19(35):3999-4010. PubMed ID: 10962556
    [Abstract] [Full Text] [Related]

  • 8. Shp-2 has a positive regulatory role in ES cell differentiation and proliferation.
    Qu CK, Feng GS.
    Oncogene; 1998 Jul 30; 17(4):433-9. PubMed ID: 9696036
    [Abstract] [Full Text] [Related]

  • 9. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.
    Kapoor GS, Zhan Y, Johnson GR, O'Rourke DM.
    Mol Cell Biol; 2004 Jan 30; 24(2):823-36. PubMed ID: 14701753
    [Abstract] [Full Text] [Related]

  • 10. SH2 domain containing protein tyrosine phosphatase 2 regulates concanavalin A-dependent secretion and activation of matrix metalloproteinase 2 via the extracellular signal-regulated kinase and p38 pathways.
    Ruhul Amin AR, Oo ML, Senga T, Suzuki N, Feng GS, Hamaguchi M.
    Cancer Res; 2003 Oct 01; 63(19):6334-9. PubMed ID: 14559821
    [Abstract] [Full Text] [Related]

  • 11. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.
    Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, Sayeski PP.
    Cell Signal; 2007 Mar 01; 19(3):600-9. PubMed ID: 17027227
    [Abstract] [Full Text] [Related]

  • 12. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
    Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, Cavenee WK.
    Cancer Res; 2002 Nov 15; 62(22):6764-9. PubMed ID: 12438278
    [Abstract] [Full Text] [Related]

  • 13. Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.
    Wang LL, Blasioli J, Plas DR, Thomas ML, Yokoyama WM.
    J Immunol; 1999 Feb 01; 162(3):1318-23. PubMed ID: 9973385
    [Abstract] [Full Text] [Related]

  • 14. SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells.
    Wu DW, Stark KC, Dunnington D, Dillon SB, Yi T, Jones C, Pelus LM.
    Blood Cells Mol Dis; 2000 Feb 01; 26(1):15-24. PubMed ID: 10772872
    [Abstract] [Full Text] [Related]

  • 15. Negative regulation of myeloid cell proliferation and function by the SH2 domain-containing tyrosine phosphatase-1.
    Dong Q, Siminovitch KA, Fialkow L, Fukushima T, Downey GP.
    J Immunol; 1999 Mar 15; 162(6):3220-30. PubMed ID: 10092773
    [Abstract] [Full Text] [Related]

  • 16. Perinuclear localization of the protein-tyrosine phosphatase SHP-1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in A431 cells.
    Tenev T, Böhmer SA, Kaufmann R, Frese S, Bittorf T, Beckers T, Böhmer FD.
    Eur J Cell Biol; 2000 Apr 15; 79(4):261-71. PubMed ID: 10826494
    [Abstract] [Full Text] [Related]

  • 17. Progressive changes in the leukemogenic signaling in BCR/ABL-transformed cells.
    Nieborowska-Skorska M, Slupianek A, Skorski T.
    Oncogene; 2000 Aug 24; 19(36):4117-24. PubMed ID: 10962572
    [Abstract] [Full Text] [Related]

  • 18. Regulation of interleukin-3-induced substrate phosphorylation and cell survival by SHP-2 (Src-homology protein tyrosine phosphatase 2).
    Wheadon H, Edmead C, Welham MJ.
    Biochem J; 2003 Nov 15; 376(Pt 1):147-57. PubMed ID: 12935294
    [Abstract] [Full Text] [Related]

  • 19. Localization and down-regulating role of the protein tyrosine phosphatase PTP2C in membrane ruffles of PDGF-stimulated cells.
    Cossette LJ, Hoglinger O, Mou L, Shen SH.
    Exp Cell Res; 1996 Mar 15; 223(2):459-66. PubMed ID: 8601424
    [Abstract] [Full Text] [Related]

  • 20. Shp-2 mediates v-Src-induced morphological changes and activation of the anti-apoptotic protein kinase Akt.
    Hakak Y, Hsu YS, Martin GS.
    Oncogene; 2000 Jun 29; 19(28):3164-71. PubMed ID: 10918571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.